Keytruda is a brand name for the drug pembrolizumab, which is a monoclonal antibody used to treat cancer. The drug works by blocking a protein called PD-1 on the surface of immune cells, which can help the immune system recognize and attack cancer cells [1].

According to the official website for Keytruda, the drug is approved for the treatment of several types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, cervical cancer, and hepatocellular carcinoma [2].

However, eligibility for Keytruda therapy may depend on several factors, including the type and stage of cancer, as well as the patient's overall health and medical history. A study published in JAMA Network Open found that patients with non-small cell lung cancer who had higher levels of PD-L1 expression were more likely to respond to pembrolizumab therapy [3].

It is important to note that Keytruda is a prescription drug and should only be used under the guidance of a healthcare professional. Patients should discuss their eligibility for Keytruda therapy with their doctor, who can help determine if the drug is appropriate for their specific situation.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytrudahcp.com/approved-indications/
[3] https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2732329